Power3 Kills Deal to Buy StemTronix | GenomeWeb

Power3 Medical Products this week said that it is terminating its merger agreement with StemTronix but is evaluating other possible acquisitions to augment its internal development programs.

The agreement to acquire StemTronix — a Texas company focused on developing stem cell-based therapeutics for tissue repair — was announced on Feb. 11. This week Power3 said a statement that it "temporarily restrained from completing [the deal] due to issues solely related to StemTronix."

Power3 did not elaborate on those issues.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.